Advertisement

Topics

DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar

02:47 EDT 4 Aug 2017 | RTTNews

Today's Daily Dose brings you news about FDA approval of AbbVie's new hepatitis C drug; ARCA biopharma's anticipated milestones; the delay in approval of Dynavax's experimental hepatitis B vaccine; the approval of the first new chemotherapy advance in the U.S. in more than 40 years for adults with certain types of AML, and the clinical trial catalysts to watch out for in Otonomy.

Original Article: DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar

NEXT ARTICLE

More From BioPortfolio on "DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...